

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>GOLDSMITH MARK A</u> (Last) (First) (Middle) <u>C/O REVOLUTION MEDICINES, INC.</u> <u>700 SAGINAW DRIVE</u> (Street) <u>REDWOOD CITY CA 94063</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Revolution Medicines, Inc. [RVMD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/01/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/01/2024		M ⁽¹⁾		9,100	A	\$4.09	309,270 ⁽²⁾	D	
Common Stock	11/01/2024		S ⁽¹⁾		9,100	D	\$55.0235 ⁽³⁾	300,170 ⁽²⁾	D	
Common Stock	11/01/2024		S ⁽¹⁾		5,000	D	\$55.0268 ⁽⁴⁾	20,424	I	Trust ⁽⁵⁾
Common Stock	11/01/2024		S ⁽¹⁾		5,000	D	\$55.0209 ⁽⁴⁾	20,424	I	Trust ⁽⁶⁾
Common Stock								465,604	I	Trust ⁽⁷⁾
Common Stock	11/04/2024		M ⁽¹⁾		50,900	A	\$4.09	351,070 ⁽²⁾	D	
Common Stock	11/04/2024		S ⁽¹⁾		50,900	D	\$55.5564 ⁽⁸⁾	300,170 ⁽²⁾	D	
Common Stock	11/04/2024		M ⁽¹⁾		36,600	A	\$0.49	336,770 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$4.09	11/01/2024		M ⁽¹⁾			9,100	03/13/2023	03/12/2029	Common Stock	9,100	\$0	232,129	D	
Stock Option (Right to Buy)	\$4.09	11/04/2024		M ⁽¹⁾			50,900	03/13/2023	03/12/2029	Common Stock	50,900	\$0	181,229	D	
Stock Option (Right to Buy)	\$0.49	11/04/2024		M ⁽¹⁾			36,600	12/01/2020	03/20/2027	Common Stock	36,600	\$0	30,846	D	

Explanation of Responses:

- Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023.
- Includes 188,750 restricted stock units.
- This transaction was executed in multiple trades in prices ranging from \$55.00 to \$55.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from \$55.00 to \$55.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Held by Jonathan Goldsmith Revocable Trust.
- Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

7. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

8. This transaction was executed in multiple trades in prices ranging from \$55.00 to \$55.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer

/s/ Jack Anders, as attorney-in
fact for Mark A. Goldsmith 11/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.